Radiology

Butterfly Network to Host Investor Day on Monday, March 18, 2024, at the New York Stock Exchange

Retrieved on: 
Thursday, February 22, 2024

Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.

Key Points: 
  • Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.
  • During the event, Butterfly’s executive management team will present the Company’s product, software and services portfolio within the point-of-care ultrasound landscape, as well as its strategic initiatives, technology roadmap, and overarching vision.
  • The agenda will include live demonstrations of products, including the newly released, next-generation Butterfly iQ3™.
  • A copy of the presentation materials and replay of the event will be available following the event on Butterfly’s Events & Presentations page on the investor relations website.

AIXSCAN, INC. ARC60 Started Imaging Patients in the U.S.

Retrieved on: 
Thursday, February 22, 2024

The AIxSCAN, Inc. team is very pleased with the early ARC60 imaging results, both in terms of depiction of details and consistency of imaging quality.

Key Points: 
  • The AIxSCAN, Inc. team is very pleased with the early ARC60 imaging results, both in terms of depiction of details and consistency of imaging quality.
  • AIxSCAN, Inc. received additional seed funding in early September 2023 to support clinical trials and engineering projects.
  • AIxSCAN, Inc. is also in final discussions to partner with three more institutions as soon as additional ARC60 units come out of production.
  • Advisory Board member, is also very impressed with the ARC60 imaging platform capabilities.

Longevity Company, NOVOS, Launches Daily Chew That Optimizes and Maintains Essential Organ Function

Retrieved on: 
Wednesday, February 21, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240221220764/en/
    Formulation maintains and enhances seven vital organs that decline with age: brain, eyes, heart, liver, kidneys, gut, and muscles.
  • Combating these bodily declines that come with aging, NOVOS longevity supplements are critical for enhanced healthspan and lifespan.
  • “Everything we do at NOVOS is in support of accessible, enhanced longevity for everyday people,” said longevity expert, Chris Mirable, Founder and CEO of NOVOS.
  • “Optimization of our physiological function throughout the lifespan is critical for longevity, and our essential organ system is central to that.

GenesisCare Emerges from Successful Chapter 11 Reorganization

Retrieved on: 
Tuesday, February 20, 2024

GenesisCare, a leading oncology and multispecialty network, has announced the successful completion of its reorganization process and emergence on February 16 from Chapter 11 protection.

Key Points: 
  • GenesisCare, a leading oncology and multispecialty network, has announced the successful completion of its reorganization process and emergence on February 16 from Chapter 11 protection.
  • As part of its reorganization, GenesisCare will operate as four distinct businesses: a U.S. business, a business in Australia, one in the U.K., and one in Spain.
  • GenesisCare U.S. has secured new investment in its business going forward.
  • Operational improvements were also implemented throughout the organization to enhance efficiency and reduce costs, ensuring a more competitive market position.

Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum

Retrieved on: 
Tuesday, February 20, 2024

The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.

Key Points: 
  • The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.
  • “This data advances the potential for image-guided surgery to detect small tumors and metastases to organs in the peritoneal cavity which could provide better outcomes for our patients,” said Dr. Cusack.
  • “Further innovation is desperately needed to improve the benefits of cytoreductive surgery for this invasive and elusive cancer.
  • Everything we do at Lumicell is focused on improving surgical outcomes for patients,” said Howard Hechler, President of Lumicell.

XiFin Appoints Erik Sallee as Chief Financial Officer

Retrieved on: 
Wednesday, February 21, 2024

XiFin, Inc. , a leading provider of innovative healthcare information technologies and services that deliver artificial intelligence (AI)-enabled operational efficiency, interoperability, and simplicity, announced today that it has appointed Erik Sallee as its new chief financial officer and executive vice president.

Key Points: 
  • XiFin, Inc. , a leading provider of innovative healthcare information technologies and services that deliver artificial intelligence (AI)-enabled operational efficiency, interoperability, and simplicity, announced today that it has appointed Erik Sallee as its new chief financial officer and executive vice president.
  • View the full release here: https://www.businesswire.com/news/home/20240220547609/en/
    Prior to joining XiFin, Sallee was CFO at Intuitive Machines (NASDAQ: LUNR), a diversified space exploration company recognized for leading the United States’ return to the moon for the first time since Apollo.
  • “Erik’s exceptional standing as a financial leader and his track record of shaping financial strategies for innovative and swiftly growing enterprises are vital to XiFin,” said XiFin Executive Chair and Chief Executive Officer Lâle White.
  • Sallee began his career in the U.S. Marine Corps, and has since held various senior and executive finance roles.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on: 
Tuesday, February 20, 2024

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points: 
  • The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
  • In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
  • “These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

Radiation Oncology Expert and Cancer Researcher Dr. Daniel Vanderbilt Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Tuesday, February 20, 2024

is pleased to announce that Daniel B. Vanderbilt, MD, PhD , has joined its care team .

Key Points: 
  • is pleased to announce that Daniel B. Vanderbilt, MD, PhD , has joined its care team .
  • Specialty trained in radiation oncology with a doctorate in cancer cell biology, Dr. Vanderbilt has vast experience in researching, diagnosing and treating cancers utilizing the latest technologies.
  • The Associated Medical Professionals of NY multi-specialty practice spans 19 locations in Central New York, including ten offices and nine hospitals.
  • Dr. Vanderbilt will be based in A.M.P.’s office at 2 Ellinwood Drive in New Hartford, NY 13413.

Serving Patients and Communities Through Comprehensive Care Solutions: OSF HealthCare, Pointcore, Inc. and GE HealthCare Enter Strategic Care Alliance

Retrieved on: 
Monday, February 19, 2024

It will also support the Mission of OSF HealthCare to deliver exceptional care to patients in the communities they serve.

Key Points: 
  • It will also support the Mission of OSF HealthCare to deliver exceptional care to patients in the communities they serve.
  • OSF HealthCare, Pointcore and GE HealthCare expect to explore ways to scale their approach to drive greater access to personalized care for more patients.
  • The alliance will concentrate on enhancing precision care in oncology by identifying clinical and technological opportunities that can help accelerate integrated cancer care at OSF HealthCare.
  • “OSF HealthCare, Pointcore and GE HealthCare are doing this together through integrated technology, digital solutions, advanced analytics and dedicated clinical and operational specialists.

ICPO Foundation and SBMN Enter Strategic Partnership to Promote International Education Standards and Training Support in Brazil

Retrieved on: 
Tuesday, February 20, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240219353852/en/
    ICPO Foundation and SBMN enter strategic partnership to promote international education standards and training support in Brazil.
  • As part of this collaboration, ICPO and SBMN will work to revolutionize Radiomolecular Precision Oncology in Brazil, with a focus on elevating patient care, education, and research on a global scale.
  • Practical training sessions will also be conducted in Brazil at carefully selected ICPO Collaborating Centers, in a collaborative effort between SBMN and ICPO.
  • ICPO will also formulate the fundamental certification path for the ICPO Academy and the practical training curriculum in collaboration with ICPO Collaborating Centers, with SBMN providing essential support in Brazil.